Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company focused on
acquiring, developing and commercializing diagnostic tests and risk assessment
technologies for unmet clinical needs, in conjunction with Pear Healthcare
Solutions, today announces the accreditation of a national program for
pharmacists with the course name Cardiovascular Risk Assessment: Focus on
Non-Invasive Skin Cholesterol Screening. 


All Canadian pharmacists are under obligation by their respective provincial
authorities to engage in lifelong learning and competency enhancements that
supports optimal, patient centered, outcome focused care through medication
management and effective pharmacy practice. With the national accreditation of
the cardiovascular (CV) risk assessment education program, Canadian pharmacists
can now earn credits to meet this requirement by learning about the benefits of
providing CV risk assessment onsite, and skin cholesterol's role within that
environment as an emerging biomarker in coronary artery disease risk assessment
and screening.


The three modules of the program available at www.healthelearning.ca include:



Module 1 -    Cardiovascular Risk Assessment Background        (0.50 CEU)   
                                                                            
Module 2 -    Non-invasive Skin Cholesterol Testing as an      (0.50 CEU)   
              Option for CV Risk Assessment                                 
                                                                            
Module 3 -    Communication and Action Plans                   (0.50 CEU)   



"The retail pharmacy segment is an important distribution channel for the
PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test," said
Christopher J. Moreau, President and CEO of Miraculins Inc. "The newly
accredited program for cardiovascular risk assessment is another important step
forward in educating pharmacists about the science and biology of skin
cholesterol and its role in coronary artery disease risk assessment. This will
provide a very important educational foundation for pharmacists as we work in
parallel towards offering the PreVu POC Test to all potentially at-risk
Canadians through additional national, regional and independent pharmacy
locations."


About the PreVu Non-Invasive Skin Cholesterol Test 

The PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test is a
non-invasive, risk assessment technology designed to measure skin cholesterol -
an emerging biomarker in helping to assess risk of coronary artery disease
("CAD"). The PreVu(R) POC Test is completely painless, non-invasive, involves no
blood draw or needles, and requires no overnight fasting. The test is conducted
on the palm of the hand in less than 5 minutes with results being immediately
available, facilitating point of care consultation and a next steps discussion.
Skin cholesterol is the cholesterol that has been deposited and diffused into
tissue, as opposed to freely circulating in the bloodstream, and the skin
contains approximately 11% of all the cholesterol found in the human body, by
weight. Elevated skin cholesterol has been shown in clinical studies to be
strongly associated with an increased risk of significant CAD as measured by
treadmill stress testing and coronary angiography, as well as measured by
testing for coronary calcium, carotid artery thickening, and carotid artery
plaque. The PreVu POC Test does not diagnose the presence or absence of CAD, but
helps to identify patients who may be at higher, hidden risk for CAD by
measuring their levels of skin cholesterol. The PreVu POC Test is not a
substitute or replacement for blood serum cholesterol testing. For more
information visit www.prevu.com.


About Pear Healthcare Solutions

Pear Healthcare Solutions is a privately held company specializing in the
development and implementation of programs to address the evolving needs of
pharmacists in their expanding role of providing healthcare and disease
management services. Pear Healthcare Solutions offers a number of innovative
medical devices and professional education programs that help pharmacies connect
with their patients, improving their health and wellness. Pear provides
distribution, training and support/education services. For more information
visit www.pearhealthcare.com.


About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and
commercializing non-invasive tests for unmet clinical needs. A significant
number of promising diagnostic opportunities remain un-commercialized because of
the sizable gap between the discovery stage, when research institutions are
typically involved, and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in bridging this
gap. The Company's PreVu(R) technology is a revolutionary new coronary artery
disease risk assessment technology that measures cholesterol levels in a
patient's skin non-invasively, painlessly and without the need for fasting.
Miraculins is also advancing a suite of biomarkers to aid in the early detection
of the devastating disease of pregnancy known as preeclampsia. The Company's
preeclampsia program is partnered with Alere Inc., one of the world's largest
diagnostic companies. For more information visit www.miraculins.com.


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, "forward-looking statements"). These forward-looking
statements relate to, among other things, our objectives, goals, targets,
strategies, intentions, plans, beliefs, estimates and outlook, including,
without limitation, our anticipated future operating results, and can, in some
cases, be identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar expressions. In
addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking
statements.


These statements reflect management's current beliefs and are based on
information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: Miraculins' early stage of
development, lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development, rapid
technological change, uncertainties related to forecasts, competition, potential
product liability, additional financing requirements and access to capital,
unproven markets, supply of raw materials, income tax matters, management of
growth, partnerships for development and commercialization of technology,
effects of insurers' willingness to pay for products, system failures,
dependence on key personnel, foreign currency risk, risks related to regulatory
matters and risks related to intellectual property and other risks detailed from
time to time in Miraculins' filings with Canadian securities regulatory
authorities, as well as Miraculins' ability to anticipate and manage the risks
associated with the foregoing. Additional information about these factors and
about the material factors or assumptions underlying such forward-looking
statements may be found in the body of this news release. Miraculins cautions
that the foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking statements to make
decisions with respect to Miraculins investors and others should carefully
consider the foregoing factors and other uncertainties and potential events.


These risks and uncertainties should be considered carefully and prospective
investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press release are
based upon what management believes to be reasonable assumptions, Miraculins
cannot provide assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to update or
revise any forward-looking statement. 


PreVu(R) is a registered trademark of Miraculins Inc. All Rights Reserved. 2013.

FOR FURTHER INFORMATION PLEASE CONTACT: 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1596 (FAX)
info@miraculins.com
www.miraculins.com
Colonial Coal (TSXV:CAD)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more Colonial Coal Charts.
Colonial Coal (TSXV:CAD)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more Colonial Coal Charts.